- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03383705
VBeam Prima for Treatment of Photoaged Facial Skin
December 19, 2017 updated by: Syneron Medical
This is an open-label, single-center study.
Subjects in this study will receive up to four (4) facial treatments at 4-6 (±1) weeks interval, with the VBeam Prima device according to the study protocol.
Subjects will return for follow-up (FU) visits at the clinic at 1 and 3 months following the last treatment.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gilly Munavalli, MD
- Phone Number: (704) 375-6766
- Email: info@carolinaskin.com
Study Contact Backup
- Name: Cindy Tucker, RN-C
- Phone Number: (704) 375-6766
- Email: info@carolinaskin.com
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Recruiting
- Dermatology, Laser & Vein Specialists of the Carolinas
-
Contact:
- Cindy Tucker, RN-C
- Phone Number: 704-375-6766
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy Male or Female at least 18 years of age
- Photoaged facial skin with clinically visible background erythema, telangiectasia, or pigmented lesions
- Fitzpatrick Elastosis Score 2-9
- Fitzpatrick Skin Type I - VI
- Able to read, understand and sign the Informed Consent Form
- Willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions
- Willing to have limited sun exposure for the duration of the study, including the follow-up period
- Willing to have photographs taken of the treated area which will be used, de-identified, in evaluations and may be used, de-identified, in presentations and/or publications
- For female candidates - subject must be post-menopausal, or surgically sterilized, or using a medically acceptable form of birth control during the entire course of the study.
Exclusion Criteria:
- Pregnant or planning to become pregnant during the study duration.
- Implant in the treated area (such as metal plates or screws) or an injected chemical substance.
- Known collagen (connective tissue) disorder, vascular disease (i.e. saphenous reflux), scleroderma or other autoimmune disease (i.e. rheumatoid arthritis, lupus).
- History of diseases stimulated by heat or sun exposure, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- Undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions.
- Significant concurrent illness, such as such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders.
- Infection or are suffering from a current or a history of significant skin conditions in the treated area and/or inflammatory skin conditions, including, but not limited to: photodermatoses, psoriasis, eczema, rash, severe open wound stage rosacea, open cuts or scrapes and active cold sores or herpes sores prior to study treatment or during the study treatment course.
- Anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use might be requested as per the subject's physician discretion).
- Use of aspirin or pain relievers from the ibuprofen family (e.g., Motrin®, Advil®, or Naprosyn®) on a regular basis or would be taking any of these pain relievers one week before and after each study treatment session.
- History of keloid scarring or of abnormal wound healing.
- Photosensitivity to the device's laser wavelengths, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light.
- Surgical, light-based therapy or RF procedures in the treatment area within 3 months of treatment or during the study.
- Any other surgery in the treated area within 3 months of treatment (or more if skin has not healed completely) or during the study.
- Tattoo or permanent make-up in the treated area.
- Systemica use of retinoids (i.e. Retin-A®, Accutane®) or antioxidants (i.e. Restylane®, Strivectin®) within 2 months of study treatment or during the study.
- Excessive tan in areas to be treated or unable/unlikely to refrain from tanning during the study.
- Participation in a study of another device or drug within three months prior to enrollment or during the study.
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
|
Up to four treatments will be performed every 4-6 (±1) weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global Improvement Scale
Time Frame: 1 or 3 months post last treatment
|
Overall improvement using Global Improvement Scale (0=no response; 4=excellent response).
|
1 or 3 months post last treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wrinkle and Elastosis Score
Time Frame: Pre Tx.4, 1 month and 3 months post final treatment
|
Improvement using Fitzpatrick Wrinkle Class and Elastosis Score
|
Pre Tx.4, 1 month and 3 months post final treatment
|
Treatment discomfort based on NRS Scale
Time Frame: Immediately post treatment
|
Evaluate treatment discomfort based on NRS Scale as reported by study subjects
|
Immediately post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2017
Primary Completion (Anticipated)
November 15, 2018
Study Completion (Anticipated)
November 15, 2018
Study Registration Dates
First Submitted
December 7, 2017
First Submitted That Met QC Criteria
December 19, 2017
First Posted (Actual)
December 26, 2017
Study Record Updates
Last Update Posted (Actual)
December 26, 2017
Last Update Submitted That Met QC Criteria
December 19, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHF24491
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Photoaged Facial Skin
-
Galderma R&DCompletedPhotoaged SkinUnited Kingdom
-
University of MichiganRecruiting
-
University of MichiganCompleted
-
Stemedica Cell Technologies, Inc.Active, not recruitingDermatologic Disorders | Chronic Effect of Ultraviolet Radiation on Photoaged SkinUnited States
-
Skin Laser & Surgery SpecialistsCompletedPhotoaged Thinning of the Hands
-
University of PittsburghRecruiting
-
4Life Research, LLCCompletedSin Health | Skin Hydration | Skin Wrinkles | Skin Porphyrins | Facial Skin Red Spots | Facial Skin Red VasculatureUnited States
-
Alma LasersNot yet recruiting
-
Assistance Publique Hopitaux De MarseilleCompletedFacial Skin RemodelingFrance
-
University of California, DavisCompletedErythema | Wrinkles | Transepidermal Water Loss | Sebum Production | Stool Microbiome | Facial Brrightness | Facial ShineUnited States
Clinical Trials on VBeam Prima
-
Pixium Vision SAPixium Vision LLC acts as sponosor in the US on behalf of Pixium Vision SAActive, not recruitingDry Age-related Macular DegenerationUnited States
-
Pixium Vision SAActive, not recruitingDry Age-related Macular DegenerationFrance
-
Fralex TherapeuticsPharmaNetTerminatedChronic Musculoskeletal Pain
-
Fralex TherapeuticsPharmaNet; McDougall Scientific LimitedTerminatedPain | FibromyalgiaUnited States, Canada
-
Candela CorporationCompletedErythematotelangiectatic RosaceaUnited States
-
Syneron MedicalCompleted
-
Pixium Vision SAActive, not recruitingGeographic AtrophyGermany, France, Italy, Netherlands, Spain, United Kingdom
-
Limacorporate S.p.aIqvia Pty LtdNot yet recruitingArthroplasty | Replacement | Shoulder
-
Northwestern UniversityCompleted
-
The Cleveland ClinicTerminatedAbdominoplasty ScarsUnited States